US8044023B2 - Hepatitis C virus inhibitors - Google Patents

Hepatitis C virus inhibitors Download PDF

Info

Publication number
US8044023B2
US8044023B2 US12/473,741 US47374109A US8044023B2 US 8044023 B2 US8044023 B2 US 8044023B2 US 47374109 A US47374109 A US 47374109A US 8044023 B2 US8044023 B2 US 8044023B2
Authority
US
United States
Prior art keywords
hcv
compound
pharmaceutically acceptable
hz
selected
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active, expires
Application number
US12/473,741
Other versions
US20090297472A1 (en
Inventor
Alan Xiangdong Wang
Paul Michael Scola
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US5695208P priority Critical
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Priority to US12/473,741 priority patent/US8044023B2/en
Assigned to BRISTOL-MYERS SQUIBB COMPANY reassignment BRISTOL-MYERS SQUIBB COMPANY ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: WANG, ALAN XIANGDONG, SCOLA, PAUL MICHAEL
Publication of US20090297472A1 publication Critical patent/US20090297472A1/en
Application granted granted Critical
Publication of US8044023B2 publication Critical patent/US8044023B2/en
Application status is Active legal-status Critical
Adjusted expiration legal-status Critical

Links